Description
Armin Ghobadi is an Associate Professor in the Division of Oncology and clinical director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine in St. Louis, and a member of the Alvin J. Siteman Cancer Center. He earned his Medical Diploma at Iran University of Medical Sciences and Health Services School of Medicine in Tehran. Ghobadi’s post graduate training has been at the University of Texas Southwestern Medical School in Dallas, TX, the MD Anderson Cancer Center in Houston, TX and Washington University School of Medicine in St. Louis. Currently his research focuses on cellular therapy for hematologic malignancies, hematopoietic stem cell transplantation, and genome sequencing John F. DiPersio is the Deputy Director of Alvin J. Siteman Cancer Center, Samuel J. Goldman Endowed Professor of Oncology, Chief of the Division of Oncology, and director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine inSt. Louis. DiPersio earned a BA in Biology at Williams College in Williamstown, MA and a Ph.D./MD in Microbiology at the University of Rochester, Rochester, NY. Currently, his research focuses on hematopoietic stem cell mobilization, murine models of graft-versus host disease and graft-versus leukemia, leukemia genomics and targeted cellular therapies for the treatment of leukemias. Part I: Overview 1. The History of Cellular Therapies 2. Basics of Immunity Part II: CAR-T 3. Biology of CAR-T 4. Cell Types Used for CAR-T Generation 5. Combination Therapeutics with CAR-T Cell Therapy 6. Safety Switches Used for Cellular Therapies 7. Off the Shelf CAR-T 8. Manufacturing of CAR-T Cells: the Assembly Line 9. Navigating Regulations in Gene and Cell Immunotherapy 10. Bringing CAR-T to the Clinic 11. CAR-T Cell Complications 12. Mechanisms of Resistance and Relapse after CAR-T Cell Therapy Part III: TIL 13. Tumor Infiltrating Lymphocytes (TIL): From Bench to Bedside Part IV: TCR 14. T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic Part V: Viral CTLs 15. Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside Part VI: NK Cell 16. Biology of NK Cells and NK Cells in Clinic Part VII: T/NK cell engagers 17. Biology and Clinical Evaluation of T/NK Cell Engagers Part VIII: Logistics 18. Roadmap for Starting an Outpatient Cellular Therapy Program
